PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Disease Reportsarthritis
MeSH D001168 - arthritis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D007592:Joint diseases
$
Success rate
D001168: 
Arthritis
$
Success rate
D001169:Experimental arthritis
0 Companies
0 Drugs
Success rate
D001170:Infectious arthritis
$
Success rate
D001171:Juvenile arthritis
D001172:Rheumatoid arthritis
D002805:Chondrocalcinosis
0 Companies
0 Drugs
Success rate
D010003:Osteoarthritis
D010489:Periarthritis
0 Companies
0 Drugs
Success rate
D012213:Rheumatic fever
D015535:Psoriatic arthritis
D025241:Spondylarthritis
$
Success rate
D058566:Sacroiliitis
0 Companies
0 Drugs
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
AbbVieAdalimumab Humira  2003-09-08 $11,935 M Q3/23-Q2/24 
AmgenAdalimumab Amgevita  2017-03-21   
Boehringer IngelheimAdalimumab Cyltezo  2017-11-10   
Bristol Myers SquibbAbatacept Orencia  2007-05-21 $3,667 M Q4/23-Q3/24 
CelltrionAdalimumab Yuflyma  2021-02-11   
Fresenius KabiAdalimumab Idacio  2019-04-02   
Adalimumab Kromeya  2019-04-02   
Tocilizumab Tyenne  2023-09-15   
Hisamitsu PharmaceuticalMenthol, Methyl salicylate Salonpas 2027-08-01 2008-02-20   
Nordic PharmaMethotrexate Nordimet  2016-08-18   
NovartisCanakinumab Ilaris  2009-10-23 $1,206 M Q2/21-Q2/24 
PfizerAdalimumab Amsparity  2020-02-13   
Etanercept Enbrel  2000-02-02 $830 M Y2023 
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
85%
17/20
Phase 2
43%
9/21
Phase 3
39%
11/28
Approved: 4Overall Success rate: 14%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
AbbVie
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use